Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Debaters Andres Chang, MD, PhD, and Jean Louise Koff, MD, MS, led the verbal battle at the Debates and Didactics in Hematology and Oncology Conference held from July 25 to 28, 2024, in Sea Island, ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to ...

To provide more robust evidence for clinicians, investigators analyzed the efficacy and safety of biologics in patients with lupus nephritis using meta-regression analyses that adjusted for trials’ ...

The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...

Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...

Roche (RHHBY) announced that the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in patients with active lupus nephritis ...

A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).

Examples of immunotherapy are Rituxan (rituximab), Gazyva (obinutuzumab), and Arzerra (ofatumumab). Chemotherapy medications kill rapidly dividing cells. Unfortunately, chemotherapy can’t tell the ...

The trial met its primary endpoint showing a significant improvement in complete renal response with obinutuzumab with standard therapy vs standard therapy alone after 76 weeks. Positive topline ...